


# COAGULATION MECHANISMS

*DR SYED SHAHID HABIB*  
Professor & Consultant Clinical Physiology  
Dept. of Physiology  
College of Medicine & KKHU



Vessel injury



**Antithrombogenic**  
(Favors fluid blood)

**Thrombogenic**  
(Favors clotting)

HANDOUTS...12/19/2020

# OBJECTIVES

**At the end of the lecture you should be able to...**

- ❖ **Recognize different stages of haemostasis**
- ❖ **Explain the role of platelets in haemostasis.**
- ❖ **Recognize different clotting factors & cascade of clotting.**
- ❖ **Describe the intrinsic, extrinsic and common pathway.**
- ❖ **Recognize the role of thrombin in coagulation**
- ❖ **The role of anticoagulants and their mechanism of action**

# HAEMOSTASIS

The spontaneous arrest of bleeding from ruptured blood vessels

## FOUR STEPS OF HEMOSTASIS

1. **VASCULAR PHASE** ► Vascular Spasm
2. **PLATELET PHASE** ► Formation of platelet plug
3. **COAGULATION PHASE** ► Blood Coagulation & Clot Retraction
4. **FIBRINOLYTIC PHASE** ► Fibrinolysis

# 1-VASCULAR SPASM (Vascular Constriction)

Immediately After injury there is localized Vasoconstriction.

## ❖ Causative Factors are three (3)


1. Nervous reflexes
2. Local myogenic spasm
3. Local humoral factors....Platelets → Thromboxane A<sub>2</sub> [TXA<sub>2</sub>] (Vasoconstrictor)

## ❖ Importance

- ❖ Crushing injuries → Intense spasm → No lethal loss of blood

TXA<sub>2</sub> is inhibited by aspirin...How?


# A. VASOCONSTRICTION




# 2-FORMATION OF PLATELET PLUG [PRIMARY HEMOSTASIS]

**Importance**  
▶ enough to stop bleeding from small vascular damage

- Secrete**
- prostacyclin (PGI<sub>2</sub>)
  - NO
  - ADP phosphatase








Blocked by Aspirin

## B. PRIMARY HEMOSTASIS

**ADP causes stickiness**



**Serotonin (5HT) & thromboxane A2 are vasoconstrictors**




# 3-BLOOD COAGULATION

Formation of Clot or Thrombus


## [SECONDARY HEMOSTASIS]

- ❖ Blood clotting is the transformation of blood (soluble fibrinogen) from a liquid into a solid gel form (insoluble fibrin strands)
- ❖ Pathways
  - ❖ Intrinsic
  - ❖ Extrinsic
- ❖ Begins to develop in
  - ❖ 1-2 min → Minor trauma
  - ❖ 15-20 sec → Severe trauma




**CLOT is a meshwork of fibrin fibers running in all directions entrapping blood cells, platelets and plasma.**

## C. SECONDARY HEMOSTASIS



## D. THROMBUS AND ANTITHROMBOTIC EVENTS



# MECHANISM OF CLOTTING - STEPS

1. Formation of Prothrombin activator complex (Xa+Ca+PF-3+V) by Extrinsic & Intrinsic Pathways leading to Common Pathway
2. Conversion of prothrombin into thrombin
3. Conversion of fibrinogen into fibrin
4. Fibrin converts to stable fibrin polymer



# Clotting Factors

## Guyton

### Prothrombin

- ❖ Plasma protein (Alpha<sub>2</sub> globulin)
- ❖ Mol. Wt. - 68,700
- ❖ Plasma conc. - 15 mg/dl
- ❖ Unstable protein
- ❖ Synthesized by liver
- ❖ Vitamin-K is required for synthesis

### Fibrinogen

- ❖ Mol. Wt. – 340,000
- ❖ Plasma conc. – 100 – 700 mg/dl
- ❖ Synthesized in liver

Table 36–1

### Clotting Factors in Blood and Their Synonyms

Clotting Factor	Synonyms
Fibrinogen	Factor I
Prothrombin	Factor II
Tissue factor	Factor III; tissue thromboplastin
Calcium	Factor IV
Factor V	Proaccelerin; labile factor; Ac-globulin (Ac-G)
Factor VII	Serum prothrombin conversion accelerator (SPCA); proconvertin; stable factor
Factor VIII	Antihemophilic factor (AHF); antihemophilic globulin (AHG); antihemophilic factor A
Factor IX	Plasma thromboplastin component (PTC); Christmas factor; antihemophilic factor B
Factor X	Stuart factor; Stuart-Prower factor
Factor XI	Plasma thromboplastin antecedent (PTA); antihemophilic factor C
Factor XII	Hageman factor
Factor XIII	Fibrin-stabilizing factor
Prekallikrein	Fletcher factor
High-molecular-weight kininogen	Fitzgerald factor; HMWK (high-molecular-weight) kininogen
Platelets	



# Clotting Factors

Ganong

**TABLE 31–5** System for naming blood-clotting factors.

Factor <sup>a</sup>	Names
I	Fibrinogen
II	Prothrombin
III	Thromboplastin
IV	Calcium
V	Proaccelerin, labile factor, accelerator globulin
VII	Proconvertin, SPCA, stable factor
VIII	Antihemophilic factor (AHF), antihemophilic factor A, antihemophilic globulin (AHG)
IX	Plasma thromboplastic component (PTC), Christmas factor, antihemophilic factor B
X	Stuart–Prower factor
XI	Plasma thromboplastin antecedent (PTA), antihemophilic factor C
XII	Hageman factor, glass factor
XIII	Fibrin-stabilizing factor, Laki–Lorand factor
HMW-K	High-molecular-weight kininogen, Fitzgerald factor
Pre-Ka	Prekallikrein, Fletcher factor
Ka	Kallikrein
PL	Platelet phospholipid

<sup>a</sup>Factor VI is not a separate entity and has been dropped.


Intrinsic pathway

**Blood Trauma or Contact with collagen**

Extrinsic pathway

**Tissue Factor**


**Prothrombin Activator Complex**



**Fibrin Stabilizing Factor XIII**


# EXTRINSIC MECHANISM FOR INITIATING CLOTTING

TF or tissue thromboplastin; includes phospholipids from the membranes of the tissue plus a lipoprotein complex that functions mainly as a proteolytic enzyme.




# INTRINSIC MECHANISM FOR INITIATING CLOTTING

Trauma to the blood itself or exposure of the blood to collagen (from a traumatized blood vessel wall), foreign surface/glass




# ACTION OF THROMBIN ON FIBRINOGEN TO FORM FIBRIN





# ROLES OF THROMBIN IN HEMOSTASIS



# CLOT RETRACTION

- ❖ When clot retracts (contracts), it expresses most of the fluid from the clot within 20-60 min **called** → **Serum**
- ❖ Serum cannot clot
- ❖ Role of platelets in clot formation & retraction.....they are contractile.

## Fate of Clot:


**Lysis or Fibrous tissue Formation**

(platelet derived growth factor)

# LYSIS OF BLOOD CLOTS BY PLASMIN


Formed blood clot can either become fibrous or dissolve.

- Fibrinolysis (dissolving) means Breaking down of fibrin by naturally occurring enzyme plasmin → prevent intravascular blocking.



Tissue Plasminogen Activator (TPA) is used to activate plasminogen to dissolve coronary and cerebral clots.

**The  
fibrinolytic  
system and its  
regulation by  
Protein C**



USED IN VIVO

## ANTICOAGULANTS

USED IN VITRO

Parenteral

**Heparin** → Combines with antithrombin III and ↑ its effectiveness by 100-1000 fold, Also remove Factors XII, XI, X, and IX (Monitored by PTT time) →

**CANNOT BE TAKEN ORALLY; WHY?**

Oral

❖ **Warfarin:** ↓ production of Vit K dependent clotting factors (II, VII, IX and X) by liver (Monitored by PT time) →

❖ **IS ALWAYS TAKEN ORALLY**

**No  $\text{Ca}^{++}$  → No Clotting (Needed in many steps)**

**Citrate ions** → Deionization of  $\text{Ca}^{++}$

**Oxalate ions** → Precipitate the  $\text{Ca}^{++}$

**EDTA** → chelates (binds) calcium ions

**Heparin** → Binds to AT III



# NATURAL INTRAVASCULAR ANTICOAGULANTS

## 1. Endothelial Surface Factors

- ❖ Smoothness of Endothelium
- ❖ Glycocalyx Layers
- ❖ Thrombomodulin Protein binds to thrombin → Activates Protein C (with ProtS) → inactivates factors V & VIII and inactivates an inhibitor of tPA → increasing the formation of plasmin.

## 2. Antithrombin action of Fibrin and Antithrombin III

- ❖ 85-90 % Thrombin binds with Fibrin
- ❖ 10-15 % Thrombin binds with Antithrombin III

**Antithrombin III is a circulating protease blocking clot factors**

# NATURAL INTRAVASCULAR ANTICOAGULANTS

## 3. Heparin

- ❖ - vely charged conjugated polysaccharide
- ❖ Increase the effectiveness of Antithrombin III
- ❖ Produced by
  - ❖ Mast cells
  - ❖ Basophil cells
- ❖ Most widely used anticoagulant clinically e.g. in stroke

## 4. Alpha<sub>2</sub> – Macrogobulin

- ❖ Synthesized mainly in liver and acts as a binding agent for several coagulation factors and inhibits thrombin.

# **BLEEDING & CLOTTING DISORDERS**

- A. Hemophilia**
- B. Thrombocytopenia**
- c. Liver diseases & Vitamin-K deficiency**

# HEMOPHILIA

- Genetic disorders
- Hem A & B are inherited in X linked recessive pattern
- Occurs exclusively in males Females are carriers
- Hem C is autosomal recessive
- VWD autosomal dominant

## ❖ HEMOPHILIA A

❖ Classic Hemophilia

❖ 85 % cases

❖ Def. Of factor VIII

## ❖ HEMOPHILIA B (Christmas disease)

❖ 15 % cases

❖ Def. Of factor IX

## ❖ HEMOPHILIA C (Rosenthal syndrome)

❖ Def of factor XI (both sexes)

- Small Comp. → Hemophilia A ► ↑PTT
- Large Comp. → Von-Willebrand's disease ► ↑PTT & BT

Clinical Features: Easy bruising, massive bleeding after trauma or operation, hemorrhages in joints

# THROMBOCYTOPENIA

❖ Count < 50,000 ul may cause spontaneous bleeding

❖ Less than 10,000 ----- Fatal

## ❖ ETIOLOGY

### Decreased production

- ❖ Aplastic anemia
- ❖ Leukemia
- ❖ Drugs
- ❖ Infections (HIV, Measles)

### Increased destruction

- ❖ ITP
- ❖ Drugs
- ❖ Infections (HIV)

## Clinical Features

- Easy bruisability
- Epistaxis
- Gum bleeding
- Hemorrhage after minor trauma
- Petechiae/Ecchymosis





# THROMBOCYTOPENIA (cont.)

## ❖ Diagnosis

- ❖ PLT count decreased
- ❖ B.T increased

## ❖ Treatment

- ❖ Rx of the underlying cause
- ❖ PLT concentrates
- ❖ Fresh whole blood transfusion
- ❖ Splenectomy

## PSEUDOTHROMBOCYTOPENIA

- Partial clotting of specimen
- EDTA-platelet clumping
- Platelet satellitism around WBCs
- Cold agglutinins
- Giant platelets

# BLEEDING DISORDERS

## Liver diseases & Vitamin-K deficiency

- ❖ e.g. Hepatitis, Cirrhosis
  - ❖ Decreased formation of clotting factors
  - ❖ Increased clotting time
- ❖ Vitamin K dependent factors
  - ❖ Factors...II , VII, IX & X

# BLEEDING DISORDERS

## A. Vitamin-K

- ❖ Fat soluble vitamin
- ❖ Required by liver for formation 4 clotting factors

**Factors: II, VII, XI and X**

### ❖ Sources

- ❖ Diet
- ❖ Synthesized in the intestinal tract by bacteria

### ❖ Deficiency

- ❖ Malabsorption syndromes
- ❖ Biliary obstruction
- ❖ Broad spectrum antibiotics
- ❖ Dietary def (in Neonates)
- ❖ Rx.: Treat the underlying cause → Vit K injections

## 2) SCREENING TEST


Test	Mechanism Tested	Normal Value	Disorder
Bleeding time (BT)	Hemostasis, capillary & platelet function	3-7 min beyond neonate	Thrombocytopenia, von Willebrand disease
Platelet count	Platelet number	150 000 - 450 000 / mm <sup>3</sup>	Thrombocytopenia
Prothrombin time (PT)	Extrinsic & common pathway	< 12 sec beyond neonate; 12-18 sec in term neonate	Defect in Vit K-dependent factor, liver disease, DIC
Activated partial thromboplastin time (APTT)	Intrinsic & common pathway	25-40 sec beyond neonate; 70 sec in term neonate	Hemophilia, von Willebrand disease, DIC

Source from : Nelson Essential of Pediatrics 5<sup>th</sup> edition

## Haemostasis tests in hereditary coagulation disorders

	<b>Haemophilia A</b>	<b>Haemophilia B</b>	<b>VW disease</b>
Bleeding time	Normal	Normal	Prolonged
Prothrombin time	Normal	Normal	Normal
APTT	Prolonged	Prolonged	Prolonged
Factor VIII	Low	Normal	Low or normal
Factor IX	Normal	Low	Normal
VWF	Normal	Normal	Low

**Summary of reactions involved in hemostasis.**





**THANKS**





# PLATELETS STRUCTURE & FUNCTIONS

***DR SYED SHAHID HABIB***  
**MBBS DSDM PGDCR FCPS**  
**Professor & Consultant Clinical Physiology**  
**Dept. of Physiology**  
**College of Medicine & KKHU**



**HANDOUTS...12/19/2020**


# OBJECTIVES

❖ **At the end of the lecture you should be able to .....**

- ❖ **Describe formation and development of platelets**
- ❖ **Understand platelet normal ultrastructure**
- ❖ **Describe the functions of different platelets organelles and surface receptors**
- ❖ **Describe the mechanisms of platelet functions**
- ❖ **Relate membrane receptors and granule content to normal function in hemostasis and bleeding (platelet) disorders**


# PLATELETS

Formed by fragmentation from megakaryocytes



# SITE OF FORMATION

## Bone-marrow



# PLATELETS (Characteristics)

**SHAPE:** MINUTE ROUND OR OVAL DISCS

**SIZE:** 1.5-3.0  $\mu\text{m}$  IN DIAMETER


**LIFE SPAN:** 7-10 DAYS

**COUNT:** 150,000 – 300,000/ microlitre

**LOCATION:** 80% in blood & 20% in spleen (hypersplenism may lead to low platelet counts)

- ❖ Anuclear and discoid cell
- ❖ Contractile, adhesive, cell fragments.
- ❖ Store coagulation factors & enzymes
- ❖ Surface Binding Antigens Glycoproteins





# Platelet Ultrastructure

Mitochondria

Microtubules

Alpha Granules  
von Willebrand  
Factor  
Fibrinogen  
Chemokines  
(PF4, etc.)  
Thrombospondin  
P-selectin

Open canalicular  
system

Dense Granules  
ADP/ATP  
Calcium  
Serotonin





Photo by Dr. James White, in "Methods in Molecular Biology: Platelets and Megakaryocytes, Vol. 1", Gibbins, J.M., and Mahaut-Smith, M.P., [eds.], 2004, pg. 48.



# FUNCTIONAL CHARACTERISTICS

- **Motile:** Actin And Myosin Molecules
- **Active:** Endoplasmic Reticulum, Golgi Apparatus & Mitochondria
- **Enzymes** Systems such as for Synthesis Of Prostaglandins
- **Granules ( $\alpha$  &  $\delta$ )**



## Dense or $\delta$ granules


- Serotonin
- ADP
- $\text{Ca}^{++}$

## Alpha $\alpha$ granules

- Coag Factors (eg:Fibrinogen,vWF)
- PDGF
- Chemokines


# Platelets Activation

Resting platelet




GP IIb/IIIa  
receptors

Activated platelet



Fibrinogen



Aggregating platelets


4 STEPS

1. Adhesion
2. Aggregation (Needs Fibrinogen)
3. Release
4. Clot Retraction

# PLATELETS ACTIVATION

**Normal Endothelium Secrete:**

- prostacyclin (PGI<sub>2</sub>)
- NO
- ADP phosphatase



# Platelet Receptors

<https://www.youtube.com/watch?v=0pnpoEy0eYE>

(GP Ia, GP VI)  
Collagen

(TP $\alpha$ )  
TXA<sub>2</sub>

(P2Y<sub>12</sub>)  
ADP


Platelet


GP Ib-IX-V  
(vW Factor)

GP IIb-IIIa  
(Fibrinogen, vWF)

Bernard-Soulier  
Syndrome

Glanzmann  
Thrombasthenia





# CLOT RETRACTION

- ❖ When clot retracts (contracts), it expresses most of the fluid from the clot within 20-60 min **called** → **Serum**
- ❖ Serum cannot clot
- ❖ Role of platelets in clot formation & retraction.....they are contractile.

## Fate of Clot:

**Lysis or Fibrous tissue Formation**

(platelet derived growth factor)



## Activated Platelets

### Secrete:


1. ADP → Adhesion
2. 5HT → vasoconstriction
3. Platelet phospholipid (PF3) → clot formation
4. TXA<sub>2</sub> is a PG formed from arachidonic acid →

### Functions:

- vasoconstriction
- Platelet aggregation  
(TXA<sub>2</sub> is inhibited by aspirin)

### Aggregation:

Fibrinogen is needed to join platelets to each other via platelet fibrinogen receptors





# Congenital Platelet Disorders

## Disorders of Adhesion:

- Bernard-Soulier

## Disorder of Aggregation:

- Glanzmann thrombosthenia

## Disorders of Granules:

- Grey Platelet Syndrome
- Storage Pool deficiency
- Hermansky-Pudlak Synd
- Chediak-Higashi Synd

## Disorders of Cytoskeleton:

- Wiskott-Aldrich syndrome


## Disorders of Primary Secretion:

- Receptor defects (TXA<sub>2</sub>, collagen ADP, epinephrine)


## Disorders of Production:

- Congenital amegakaryocytic thrombocytopenia
- MYH9 related disorders
- Thrombocytopenia with absent radii (TAR)
- Paris-Trousseau/Jacobsen

Adhesion



Aggregation: Fibrinogen-GPIIb/IIIa



The primary platelet plug

# Testing Platelet Functions


- Peripheral smear and Platelet count
- Bleeding time (Duke Method)
- Platelet Function Analyzer (PFA-100)
- Platelet Aggregation
- Flow-cytometry
- Electron-microscopy
- Granule release products

Automated

Aggregation



Duke Method



# Laboratory Testing of Platelet Functions

❖ **By Platelet Aggregation Method:** Provides information on time course of plat. activation.

❖ **Agonists:**



- ❖ ADP
- ❖ Adrenaline
- ❖ Collagen
- ❖ Arachidonic acid
- ❖ Ristocetin
- ❖ Thrombin

❖ Reference ranges need to be determined for each agonist

You need in Platelet rich plasma (PRP)

# Agonists:

- ADP
- Adrenaline
- Collagen
- Arachidonic acid
- Ristocetin
- Thrombin




Whole blood



RBC



PRP



# FACTORS AFFECTING BLOOD PLATELET COUNT

- ❖ **AGE** : ↓ in newborn
- ❖ **Menstrual cycle**:
  - ❖ ↓ prior to menstruation
  - ❖ ↑ After menstruation
- ❖ **Pregnancy**: ↓
- ❖ **Injury**: ↑
- ❖ **Adrenaline**: ↑
- ❖ **Hypoxia**: ↑
- ❖ **Smoking**: ↓
- ❖ **Nutritional deficiencies**: ↓ eg; vitamin b12, folic acid and iron

# LAB TESTS IN BLEEDING AND CLOTTING

Test	Normal Value	Importance
PLATELET COUNT	100,000 - 400,000 CELLS/MM <sup>3</sup>	Thrombocytopenia
PLATELET FUNCTIONS	Normal Aggregation	Thrombocytopathy (normal count) [Congenital or Acquired...Aspirin]
BLEEDING TIME (BT)	2-8 MINUTES	Bleeding disorders
PROTHROMBIN TIME (PT)	10-15 SECS	Measures Effectiveness of the Extrinsic Pathway
PARTIAL THROMBOPLASTIN TIME (PTT)	25-40 SECS	Measures Effectiveness of the Intrinsic Pathway
THROMBIN TIME (TT)	9-13 SECS	A Measure of Fibrinolytic Pathway Time for Thrombin To Convert Fibrinogen ► Fibrin

$$INR = \left( \frac{PT_{test}}{PT_{normal}} \right)^{ISI}$$



# Case study

❖ A 7 years old girl complaining of severe bruising since birth and if she had injury she would bleed for days. She had epistaxis which lasted for days ,her mother said :”she just bruise more easily than her older sister.”

❖ **Investigation:**


- ❖ CBC
- ❖ RBC
- ❖ WBC
- ❖ platelet

❖ **Platelet morphology:**

Normal

❖ **Aggregometry :**

Absent platelet aggregation in response to ADP, collagen ,thrombin and epinephrine.





**Diagnosis:**  
**Glanzmann's**  
**Thrombasthenia**

## Aggregometry:


Absent platelet aggregation in response to ADP, collagen, thrombin, & epinephrine.

## Diagnosis:


**Glanzmann's  
Thrombasthenia**



1. In the patient shown below, the only abnormality is a lack of agglutination with Ristocetin. Possible diagnoses are therefore, Von Willebrand Disease or Bernard Soulier Syndrome.




2. This is the converse of the first patient and the only agglutination [and this is not complete] is seen with Ristocetin. There is no aggregation with ADP, adrenaline or collagen.



Possible diagnoses include Glanzmann's Thrombasthenia or Afibrinogenaemia.  
[ Remember, platelet agglutination with Ristocetin occurs independently of Fibrinogen.]


3. In this patient reversible, first wave aggregation is seen with ADP, adrenaline and collagen and only partial agglutination with Ristocetin. The picture is clearly different from the two traces above 1) or 2): the results suggest a failure of granule release and is consistent with either platelet Storage Pool Disorder or a defect in nucleotide release.





## Classic biphasic aggregation:


1. Baseline
2. Addition of an Agonist - this results in a change in platelet change and hence a drop in the baseline absorbance
3. Primary wave aggregation
4. Release of nucleotides
5. Secondary wave aggregation



Adrenaline and low dose ADP classically give a biphasic aggregation




# Optical Aggregometry



Disorder	Characteristic Findings on LTA
Glanzmann's Thrombasthenia OR afibrinogenaemia	Absent or markedly impaired aggregation to all agonists except Ristocetin. Ristocetin-induced agglutination shows only primary wave - aggregation cannot occur because fibrinogen cannot bind. Afibrinogenaemia gives similar results.
Bernard Soulier Syndrome OR Von Willebrand Disease	Absent or markedly reduced platelet agglutination with Ristocetin.
Storage Pool Disorder OR Platelet Release Defect	Primary aggregation only with ADP, adrenaline and collagen and only partial agglutination with Ristocetin suggesting a failure of granule release or a deficiency of platelet granules.
Aspirin [or defects in the COX pathway]	Absent aggregation to Arachidonic acid. Primary wave aggregation only with ADP. Decreased or absent aggregation with collagen.
Clopidogrel	Absent aggregation with ADP

**Aspirin inhibits platelet cyclooxygenase by irreversible acetylation, thereby preventing the formation of thromboxane A2 which is a powerful stimulant of platelet aggregation . Clopidogrel, a thienopyridine, acts by inhibiting adenosine receptors, which inhibits the early step of platelet activation**



**Key:** TXA<sub>2</sub> = thromboxane; GP = glycoprotein; ADP = adenosine diphosphate; CAMP = cyclic adenosine monophosphate

